{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:07:54Z","timestamp":1772107674318,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.semarthrit.2022.152049","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T02:19:41Z","timestamp":1655259581000},"page":"152049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-1444","authenticated-orcid":false,"given":"Ritch te","family":"Kampe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina Mai","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Hotea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"van Durme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2022.152049_bib0001","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12916-017-0878-5","article-title":"The genetics of gout: towards personalised medicine?","volume":"15","author":"Dalbeth","year":"2017","journal-title":"BMC medicine"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/OARRR.S282631","article-title":"Contentious issues in gout management: the story so far","volume":"13","author":"Talaat","year":"2021","journal-title":"Open access rheumatology: research and reviews"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152049_bib0003","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","article-title":"Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0","volume":"67","author":"Boers","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0004","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.181081","article-title":"Identifying provisional generic contextual factor domains for clinical trials in rheumatology: results from an OMERACT initiative","author":"Nielsen","year":"2019","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152049_bib0005","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.semarthrit.2021.03.013","article-title":"OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study","volume":"51","author":"Nielsen","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152049_bib0006","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/annrheumdis-2020-217237","article-title":"Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group","volume":"79","author":"Nielsen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152049_bib0007","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nature reviews Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152049_bib0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152049_bib0009","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152049_bib0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/rheumatology\/keu424","article-title":"Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review","volume":"54","author":"Araujo","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152049_bib0011","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/S2665-9913(21)00319-2","article-title":"Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials","volume":"4","author":"Stamp","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152049_bib0012","first-page":"199","article-title":"Gout and its comorbidities","volume":"68","author":"Pillinger","year":"2010","journal-title":"Bulletin of the NYU hospital for joint diseases"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0013","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0014","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ Br Med J"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152049_bib0015","article-title":"Allopurinol for chronic gout","volume":"2014","author":"Seth","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152049_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008335","article-title":"Pegloticase for chronic gout","author":"Anderson","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152049_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010457.pub2","article-title":"Uricosuric medications for chronic gout","volume":"2014","author":"Kydd","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0018","article-title":"Febuxostat for treating chronic gout","volume":"11","author":"Tayar","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"92","key":"10.1016\/j.semarthrit.2022.152049_bib0019","first-page":"63","article-title":"Interventions for Tophi in Gout: A cochrane systematic literature review","volume":"41","author":"Sriranganathan","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0020","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0021","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0022","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0023","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med Res Method"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152049_bib0024","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1037\/0033-2909.117.1.167","article-title":"Meta-analysis of screening and diagnostic tests","volume":"117","author":"Hasselblad","year":"1995","journal-title":"Psychol Bull"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152049_bib0025","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/ije\/dys124","article-title":"Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study","volume":"41","author":"da Costa","year":"2012","journal-title":"Int J Epidemiol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152049_bib0026","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7414","key":"10.1016\/j.semarthrit.2022.152049_bib0027","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0028","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9781119536604.ch10","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2019","journal-title":"Cochrane handbook for systematic reviews of interventions"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152049_bib0029","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152049_bib0030","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s10682-012-9555-5","article-title":"Methodological issues and advances in biological meta-analysis","volume":"26","author":"Nakagawa","year":"2012","journal-title":"Evolutionary Ecology"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0031","series-title":"R: A language and environment for statistical computing","author":"Team","year":"2013"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152049_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Journal of statistical software"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152049_bib0033","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Research synthesis methods"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152049_bib0034","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152049_bib0035","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152049_bib0036","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.40685","article-title":"Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis & rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152049_bib0037","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152049_bib0038","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis & rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152049_bib0039","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152049_bib0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0041","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/CLEP.S129728","article-title":"Effect modification, interaction and mediation: an overview of theoretical insights for clinical investigators","volume":"9","author":"Corraini","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152049_bib0042","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2022.152049_bib0043","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jclinepi.2021.03.009","article-title":"Effect Modifiers and Statistical Tests for Interaction in Randomized Trials","volume":"134","author":"Christensen","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"13","key":"10.1016\/j.semarthrit.2022.152049_bib0044","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"10264","key":"10.1016\/j.semarthrit.2022.152049_bib0045","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152049_bib0046","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheumatic Dis."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:08:06Z","timestamp":1758733686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":46,"alternative-id":["S0049017222001007"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152049","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152049"}}